If you are wondering whether Medpace Holdings is still priced attractively after a strong multi year run, it helps to step back and look carefully at what the current share price implies about future ...

Medpace (MEDP) closed the most recent trading day at $447.09, moving +2.06% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.54%. Elsewhere, the Dow saw an upswing ...

What Happened? A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the ...

Levi & Korsinsky, LLP is investigating Medpace Holdings, Inc. (NASDAQ: MEDP) concerning potential securities law claims on behalf of shareholders. The investigation centers on whether the company and ...

Medpace's backlog growth remains sluggish, but a healthy book-to-bill ratio and potential sector recovery could accelerate future growth. See why MEDP is a Buy.

Medpace Hldgs (NASDAQ:MEDP) is preparing to release its quarterly earnings on Monday, 2024-10-21. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Medpace beats analyst estimates on the top and bottom lines in the fourth quarter. Medpace expects full-year 2025 revenue to be in the range of $2.11 billion to $2.21 billion. Up Next: Get 5 Dark ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Medpace’s massive expansion ...

Medpace operates exclusively on a full-service basis, meaning clients hire them to run entire clinical trial phases end-to-end. The result is a business that scales through operational precision, not ...